Title: The human cortical motor map in post-stroke hemiparesis in the presence of treatment-related clinically important recovery

Authors: Tomoko Kitago^{1,2}, Joshua Silverstein³, Michael B. Gerber⁴, Charlene Thomas⁵, Linda M. Gerber^{5,6}, Gary W. Thickbroom⁷, Dylan J. Edwards^{8,9}

¹ Department of Neurology, New York Medical College, Valhalla, NY

² Department of Neurology, Westchester Medical Center, Valhalla, NY

³Cardiology Associates of Fairfield County, Stamford, NY

⁴ Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY

⁵ Department of Population Health Sciences, Weill Cornell Medicine, New York, NY

⁶ Department of Medicine, Weill Cornell Medicine, New York, NY

⁷ Department of Rehabilitation Medicine, Weill Cornell Medicine, New York, NY

⁸ Moss Rehabilitation Research Institute, Thomas Jefferson University, Philadelphia, PA

⁹ School of Biomedical and Health Sciences and Exercise Medicine Research Institute,

Edith Cowan University, Perth, Australia

Keywords: Motor map, transcranial magnetic stimulation, stroke, motor recovery

ABSTRACT

Objectives: To determine if intervention-related clinical improvement in post-stroke hemiparesis is associated with enlarged primary motor cortex representation.

Methods: Data were analyzed from a single site subset of the NICHE trial. Transcranial magnetic stimulation (TMS) motor mapping was performed in 23 participants (3-12 months post-stroke, 10 female, 40-88 yrs, baseline Fugl-Meyer Upper Extremity (FM-UE) range 13-58) before and after intervention. TMS motor maps were acquired for the extensor digitorum communis muscle (EDC) bilaterally, at 110% resting motor threshold (RMT).

Results:

Improvement on the primary outcome measure (FM-UE) was statistically and clinically significant (mean pre= $38(\pm 15)$, post= $45(\pm 16)$; p <0.001; n=23). Significant improvement was also observed on secondary impairment and activity outcome measures (p<0.05). Ipsilesional hemisphere RMT and map volume (MV) remained unchanged (RMT pre = $42(\pm 13)$, post = $41(\pm 11)$, p=0.60; MV pre =77.98(± 71.37) mV*mm², post =109.54(± 139.06) mV*mm², p=0.36). The magnitude of clinical benefit was unrelated to difference in map characteristics from pre to post (Spearman's rho= 0.06, p=0.79).

Conclusions:

Intervention-related clinical improvement of the upper limb 3-12 months following stroke, was not associated with change in motor cortex excitability or increase in motor maps. Clinical improvements may not solely rely on consistent changes in the cortical motor representation.

INTRODUCTION

Cortical reorganization has been proposed as a mechanism underlying recovery of upper limb motor deficits after stroke¹. Changes in the area that is activated by transcranial magnetic stimulation (TMS, motor map) and the summed amplitude of the motor-evoked potentials (MEPs) over the region (map volume) are considered to reflect reorganization of the cortical areas controlling a specific muscle. Several studies have demonstrated expansion of TMS motor maps in association with clinical improvements in patients undergoing rehabilitative therapy after stroke^{2,3}, suggesting that expansion of the cortical representation plays a role in therapy-induced improvements.

We acquired TMS motor maps longitudinally in a subset of participants enrolled in the multi-center Navigated Inhibitory rTMS to Contralesional Hemisphere (NICHE) randomized, controlled trial⁶. Participants underwent upper extremity task-oriented training over a six-week period (18 sessions), with each session preceded by 1 Hz active or sham repetitive TMS (rTMS). In the overall study, both active and sham rTMS groups improved significantly on upper extremity motor outcomes.

We hypothesized that clinical motor improvement would be accompanied by an increase in motor representation as measured by TMS motor maps in the ipsilesional hemisphere. We further predicted a positive correlation between TMS motor maps and changes in clinical status after training.

METHODS

Participants

A subset of participants from the NICHE study⁶ who underwent clinical assessments and TMS motor mapping before and after the six-week study intervention were included in this analysis. Participants had a unilateral ischemic or hemorrhagic stroke 3 to 12 months prior to enrollment with residual upper extremity weakness. Participants were excluded from analysis if mapping data was not available at either timepoint, due to a missed visit or inability to obtain a motor map. All participants gave written informed consent for the study, which was approved by the Institutional Review Board of the Burke Rehabilitation Hospital.

Clinical Outcomes

The primary clinical outcome was change in motor impairment (Fugl-Meyer Upper Extremity Motor Assessment, FM-UE⁷; responders defined with >5-point improvement, considered the minimal clinically important difference)⁸. Secondary measures included upper limb activity limitation assessments (Action Research Arm Test, ARAT⁹, and Wolf Motor Function Test, WMFT)¹⁰.

Transcranial Magnetic Stimulation

TMS mapping (110% RMT: extensor digitorum communis, EDC: left and right hemisphere), was conducted with Nexstim[™] neuronavigation system. A target was placed on the location of the estimated hotspot, and a targeting grid (3 x 3 mm) was overlaid over the surface of the cortex. At least one pulse was delivered in each square

of the grid that was mapped, and an effort was made to elicit at least two valid resting MEPs per square. Full details of the TMS procedures are described elsewhere⁶ and in the Supplement.

Mapping Analysis

MEPs were individually inspected and analyzed offline. Artifacts, active MEPs (defined as EMG activity >25 μ v within 100ms prior to the TMS pulse), and MEPs with a latency >25ms or <7ms were excluded from analysis. Motor mapping data were quantified using *NeuroMeasure*, an open source interactive software program¹¹. Single-point mapping data was interpolated into a continuous function using a piecewise cubic spline curve fitting algorithm. Map area and map volume (spatial extent weighted by MEP amplitude, μ V*mm²), was calculated for Pre and Post motor maps in each hemisphere¹¹.

Statistical Analysis

Statistical analyses were performed in R Version 4.2.2. Wilcoxon signed-rank test was used to compare differences in outcome measures between time points. The relationship between the changes in map volume and the changes in clinical outcomes was examined using Spearman's rank correlation. All p-values are two-sided with statistical significance evaluated at the 0.05 alpha level. As this study was exploratory, p-values were not corrected for multiple comparisons.

RESULTS

Demographics and clinical characteristics of the 23 participants are reported in Table 1. There was no difference in outcomes between participants who received active (n=15) and sham (n=8) rTMS groups, thus they were combined for analysis in the present study. There were significant improvements in FM-UE from Pre to Post, with a mean increase in FM-UE score of 7.1 (SD 4.8) points, p < 0.001 (Figure 1A, Table 1). Secondary outcomes of upper limb activity (ARAT, WMFT) also improved significantly (Table 1).

TMS motor map changes

Motor threshold remained stable for Pre to Post. At the group level, ipsilesional motor map volume did not significantly change from Pre to Post (Table 1). However, we observed high inter-individual variability in map volume changes, with an increase in map volume in some participants whereas others showed a decrease, despite clinical improvements (Figure 2). There was also no significant difference in map volume changes between clinical responders (n=16) vs. non-responders (n=7) (22.97± 80.82 vs. 51.19±150.38 mV*mm², p >0.9) or those who had cortical involvement (n=12) vs. subcortical only (n=11) (48.41±132.26 vs. 13.17±61.64 mV*mm², p >0.9).

We found no significant changes in motor map volume in the contralesional hemisphere between Pre and Post (Table 1).

Correlation of clinical changes with TMS map changes

FM-UE changes were not significantly correlated with changes in ipsilesional map volume (Spearman's rho = 0.06, p = 0.79, Figure 1B). We also examined the correlation of map changes with improvements on our secondary outcome measures (ARAT and WMFT) that assess functional tasks. There was no significant correlation between changes in ipsilesional map volume and ARAT (Spearman's rho 0.36, p=0.09), or WMFT (Spearman's rho 0.28, p=0.20).

DISCUSSION

The significant clinical improvement across three accepted outcome measures spanning impairment and activity, was not accompanied by a corresponding increase in TMS motor map volumes. This finding held irrespective of whether the lesion affected cortex or was confined to subcortical damage. Corticospinal excitability (measured by RMT) also did not significantly change in the presence of clinical improvement.

While the motor map probably reflects motor function of the upper limb at some level, clinical improvements may not solely rely on consistent changes in the cortical motor representation as measured following stimulation at the scalp. Local intracortical network changes in synaptic weighting may have accompanied improved function, that may not be captured by overall map volume.

There are other considerations in the interpretation of our results. First, due to the timing of our assessments 7 weeks after beginning of the intervention, we may have missed map changes that occurred earlier. Second, we used one muscle (EDC) for mapping,

whereas the clinical outcomes were a global measure of upper limb movement, not limited to movements directly involving the EDC muscle. It is possible that we would have observed a correlation with map changes with a more direct measure of EDC function. However, others have demonstrated that corticospinal tract integrity to distal muscles inform recovery of the entire upper limb¹². Third, the data collection technique relied on a neurosurgical mapping method with single pulses at each stimulation location with greater spatial resolution, rather than taking an average of multiple MEP responses at points that are spaced apart. This could have influenced our findings due to the inherent variability of MEP responses¹³. Finally, here we used a TMS mapping intensity of 110% RMT, while contemporary methods recommend considerably higher (>150% RMT)¹⁴.

CONCLUSIONS

Improved upper limb movement associated with intensive behavioral intervention poststroke can occur in the presence of stable corticospinal excitability and without consistent changes in motor map representation of the finger muscles. Future studies that examine longitudinal map changes with interventions should consider timing and the effect of different mapping techniques. Furthermore, the role of M1 cortical representation may need to be examined with other structural and functional brain investigational methods in the context of broader network of recovery of upper limb motor function.

ACKNOWLEDGMENTS

We would like to acknowledge Alasdair C. McLean, Samuel J. Stephen, Alex G. Chalco,

and Usman M. Arshad for development of the mapping analysis software.

N=23	Characteristic	Pre	Post	Difference	p-value
	Age in years	66.4 (SD 13.9)			
	Gender	13 male, 10 female			
	Affected hemisphere	13 left, 10 right			
	Stroke type (I/H)	19 I, 4 H			
	Time since stroke (months)	6.4 (SD 3.2)			
	Cortex involved	12 yes, 11 no			
	Baseline NIHSS	2.7 (SD 1.7)			
Clinical Outcomes	FM-UE				
	Median [IQR]	40 [24, 52]	47 [35, 57]	5.0 [3.5, 11.0]	<0.001
	Mean (SD)	38 (15)	45 (16)	7.1 (4.8)	
	ARAT				
	Median [IQR]	38 [18, 49]	40 [19, 52]	2.0 [0.0, 4.5]	0.042
	Mean (SD)	33 (18)	35 (19)	1.7 (6.8)	
	WMFT				
	Median [IQR]	67 [41, 863]	51 [32, 483]	-15 [-126, -3]	<0.001
	Mean (SD)	485 (618)	393 (585)	-91 (149)	
Neurophysiological Outcomes	Ipsilesional RMT (%MSO)				
	Median [IQR]	40 [33, 50]	38 [32, 49]	0 [-3, 2]	0.60
	Mean (SD)	42 (13)	41 (11)	-1 (9)	
	Ipsilesional Map Volume				
	(mV*mm²)	59.46 [28.44, 92.23]	51.67 [33.87, 131.90]	2.62 [-25.18, 56.09]	0.36
	Median [IQR]	77.98 (71.37)	109.54 (139.06)	31.56 (103.91)	
	Mean (SD)				
	Contralesional RMT (%MSO)				
	Median [IQR]	36 [30, 41]	35 [30, 42]	0 [-3, 1]	0.27
	Mean (SD)	38 (9)	36 (8)	-1 (4)	
					0.40
	(mv ⁻ mm ⁻)	55.78 [33.58, 127.44]	86.60 [49.17, 139.88]	9.07 [-8.14, 75.08]	0.18
	iviedian [IQR]	103.07 (114.08)	144.92 (175.43)	41.85 (173.64)	
	Mean (SD)				

Table 1. Study population and clinical and neurophysiological outcomes

Abbreviations: SD standard deviation; I – ischemic, H – hemorrhagic, NIHSS – National Institutes of Health Stroke Scale, FM-UE – Fugl-Meyer Upper Extremity, ARAT – Action Research Arm Test, WMFT – Wolf Motor Function Test, RMT – resting motor threshold, MSO – maximum stimulator output, IQR – interquartile range

Figure 1. (A) The primary outcome of motor impairment (FM-UE) improved significantly with intervention, but (B) there was no correlation between the clinical improvement and changes in motor map volume of the affected side (Spearman's rho = 0.06, p=0.79).

Figure 2. Examples of motor maps before and after intervention in the ipsilesional hemisphere for two participants.

REFERENCES

1. Grefkes C, Ward NS. Cortical reorganization after stroke: how much and how functional? *Neuroscientist*. Feb 2014;20(1):56-70. doi:10.1177/1073858413491147

2. Sawaki L, Butler AJ, Leng X, et al. Constraint-induced movement therapy results in increased motor map area in subjects 3 to 9 months after stroke. *Neurorehabil Neural Repair.* 2008;22(5):505-13. doi:10.1177/1545968308317531

3. Liepert J, Bauder H, Wolfgang HR, Miltner WH, Taub E, Weiller C. Treatmentinduced cortical reorganization after stroke in humans. *Stroke*. Jun 2000;31(6):1210-6.

4. Cortes M, Thickbroom GW, Elder J, et al. The corticomotor projection to liminallycontractable forearm muscles in chronic spinal cord injury: a transcranial magnetic stimulation study. *Spinal Cord.* Apr 2017;55(4):362-366. doi:10.1038/sc.2016.161

5. Kleim JA, Kleim ED, Cramer SC. Systematic assessment of training-induced changes in corticospinal output to hand using frameless stereotaxic transcranial magnetic stimulation. Research Support, N.I.H., Extramural. *Nature protocols*. 2007;2(7):1675-84. doi:10.1038/nprot.2007.206

6. Harvey RL, Edwards D, Dunning K, et al. Randomized Sham-Controlled Trial of Navigated Repetitive Transcranial Magnetic Stimulation for Motor Recovery in Stroke. *Stroke*. Sep 2018;49(9):2138-2146. doi:10.1161/STROKEAHA.117.020607

7. Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. *Scand J Rehabil Med.* 1975;7(1):13-31.

8. Page SJ, Fulk GD, Boyne P. Clinically important differences for the upperextremity Fugl-Meyer Scale in people with minimal to moderate impairment due to chronic stroke. *Phys Ther.* Jun 2012;92(6):791-8. doi:10.2522/ptj.20110009

9. Van der Lee JH, De Groot V, Beckerman H, Wagenaar RC, Lankhorst GJ, Bouter LM. The intra- and interrater reliability of the action research arm test: a practical test of upper extremity function in patients with stroke. *Arch Phys Med Rehabil.* Jan 2001;82(1):14-9. doi:S0003-9993(01)51301-5 [pii]

10.1053/apmr.2001.18668

10. Wolf SL, Catlin PA, Ellis M, Archer AL, Morgan B, Piacentino A. Assessing Wolf motor function test as outcome measure for research in patients after stroke. *Stroke*. Jul 2001;32(7):1635-9. doi:10.1161/01.str.32.7.1635

11. Gerber MB, McLean AC, Stephen SJ, et al. NeuroMeasure: A Software Package for Quantification of Cortical Motor Maps Using Frameless Stereotaxic Transcranial Magnetic Stimulation. *Front Neuroinform*. 2019;13:23. doi:10.3389/fninf.2019.00023

12. Stinear CM, Byblow WD, Ackerley SJ, Smith MC, Borges VM, Barber PA. PREP2: A biomarker-based algorithm for predicting upper limb function after stroke. *Ann Clin Transl Neurol*. Nov 2017;4(11):811-820. doi:10.1002/acn3.488

13. Schambra HM, Ogden RT, Martínez-Hernández IE, et al. The reliability of repeated TMS measures in older adults and in patients with subacute and chronic stroke. *Front Cell Neurosci.* 2015;9:335. doi:10.3389/fncel.2015.00335

14. Weise K, Numssen O, Kalloch B, et al. Precise motor mapping with transcranial magnetic stimulation. *Nat Protoc*. Feb 2023;18(2):293-318. doi:10.1038/s41596-022-00776-6

Figure 1



Figure 2



FM-UE 54

Participant B Cortical ischemic

ischemic



Post

FM-UE 59

Pre